Aryan Poduri's book, "GOAT Coder," teaches children how to code through hands-on exercises and uncomplicated explanations.

Chatbots can be overly agreeable. To get less agreeable responses, ask for opposing viewpoints, multiple perspectives, and a ...

Harvard's free programming classes teach you how to think, debug, and adapt in an AI-driven world where knowing code matters more than ever.

The native just-in-time compiler in Python 3.15 can speed up code by as much as 20% or more, although it’s still experimental ...

December 18, 2025: We checked for new Clash Royale codes. What are the new Clash Royale codes? If you're looking for new emotes and other freebies in Clash Royale, redeem codes are the fastest and ...

Claude Code hit $1 billion fast by transforming real developer workflows. Agentic coding built my complex iPhone app in just 11 days. Early command-line access gave Claude Code a huge adoption edge.

After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...

Indiana Attorney General Todd Rokita said he filed a civil lawsuit against the owners of a massive apartment complex in Castleton—a property that has set a state sales record twice over the past eight ...

Cybersecurity experts are warning Houstonians to think twice before they scan that next QR code. Jerry O’Brien, a partner at GuidePoint Security based in The Woodlands, told Chron that scammers are ...

Nahda Nabiilah is a writer and editor from Indonesia. She has always loved writing and playing games, so one day she decided to combine the two. Most of the time, writing gaming guides is a blast for ...

Tyler is a writer under CNET's home energy and utilities category. He came to CNET straight out of college, where he graduated from Seton Hall with a bachelor's degree in journalism. For the past ...

Recursion Pharmaceuticals currently has the industry's largest AI supercomputer. It also has partnerships with major drugmakers, but these have yet to yield major wins. Recursion'a lack of clinical ...